IB-DMD

IB-DMD is a small molecule drug candidate being developed by Innobioscience for the treatment of Duchenne Muscular Dystrophy (DMD) and skeletal muscular fibrosis. The compound is designed to inhibit the NF-κB/IKKβ signaling pathway and modulate key fibrotic mediators, including Connective Tissue Growth Factor (CTGF), Transforming Growth Factor beta 1 (TGF-β1), and Plasminogen Activator Inhibitor-1 (PAI-1). By targeting these pathways, IB-DMD aims to reduce chronic inflammation and muscle fibrosis, which are central to the progressive muscle degeneration seen in DMD. Preclinical studies suggest that IB-DMD can improve muscular function and reduce muscle damage and tearing. It is being developed in both oral and injectable formulations.